Neurogene Inc. (NGNE) Shares New NGN-401 Preclinical Data at ESGCT

Neurogene Inc. (NGNE) presented preclinical data on its NGN-401 gene therapy for Rett syndrome, showing durable protein expression and clinical improvements in trials. The therapy has received multiple FDA designations. NGN-401 is being evaluated in the Embolden registrational clinical trial, with no procedure-related adverse events reported in Phase 1/2 trials.

Neurogene (NGNE) presented preclinical and clinical data on NGN-401, a gene therapy for Rett syndrome. The data showed rapid and durable expression of MECP2 in all brain tissues, challenging prior assumptions about AAV delivery methods. Clinical improvements were observed at a median of two months, continuing through 30 months. The company also presented data supporting the use of ICV administration for broad CNS biodistribution.

JPMorgan initiated coverage of Neurogene with an overweight rating and a $60 price target, implying 132% upside. The bank's optimism is based on the company's gene therapy for Rett syndrome. Neurogene shares have fallen 32% over the past three months, partly due to broader biotech sector declines and softer Q2 results. The company plans to release new trial data in 2027, which JPMorgan sees as a potential catalyst.

JPMorgan initiated coverage on Neurogene Inc. (NASDAQ: NGNE) with an Overweight rating and a $60.00 price target, citing potential in its gene therapy NGN-401 for Rett syndrome. The stock trades at $25.87, with analysts maintaining a Strong Buy consensus. Neurogene expects key data readouts in 2H27, with a market cap of $518 million and high volatility. Recent analyst adjustments include lowered price targets from H.C. Wainwright and Canaccord, both maintaining Buy ratings.

Neurogene Inc. (NGNE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates Data from Phase 1/2 trial of NGN-401 for Rett syndrome showed 100% of participants improved in CGI-I score and gained ≥1 developmental milestone, with an average of 4.7 milestones per participan

Pfizer's ELREXFIO met primary endpoint in Phase 3 trial for multiple myeloma, showing 68% 18-month PFS. The study involved 523 patients. No new safety concerns were found. Pfizer plans regulatory submissions and future data presentations. PFE shares were down 0.34% in pre-market trading.